Senior Manager, Finance

1910 Genetics

20n Bio

3DBio Therapeutics

3T Biosciences

4D Molecular Therapeutics

64x Bio

8Biomed

A-Alpha Bio

A2 Biotherapeutics

AavantiBio

AB Studio

Abalone Bio

Abata Therapeutics

Abeona Therapeutics

Abintus Bio

Abiosciences

Absci

Accelevir Diagnostics

Accent Therapeutics

ACELYRIN

Acepodia

Achieve Life Sciences

Acrivon Therapeutics

Acutis Diagnostics

Adaptive Phage Therapeutics

Adcentrx Therapeutics

Adicet Bio

Aditum Bio

adMare BioInnovations

Admera Health

Adverum Biotechnologies

adyn

Aeglea BioTherapeutics

Aether Bio

Affini-T Therapeutics

Affinia Therapeutics

Affinivax

AgBiome

Agena Bioscience

Akero Therapeutics

Akouos

Alamar Biosciences

Alector

AlivaMab Discovery Services

Alkahest

Alladapt Immunotherapeutics

Allakos

Allarta Life Science

Allay Therapeutics

AlloVir

Alloy Therapeutics

AllStripes

Alltrna

Alpine Immune Sciences

Altis Biosystems

Alto Neuroscience

AltPep

Alumis

Alveo Technologies

ALX Oncology

Alzheon

Ambagon Therapeutics

Amberstone Biosciences

Ambys Medicines

Amylyx

AN2 Therapeutics

Andes

Angiocrine Bioscience

AnHeart Therapeutics

Annexon Biosciences

Ansa Biotechnologies

Antheia

Apollomics

Appia Bio

Applied Molecular Transport

Apriori Bio (Flagship)

Aptevo Therapeutics

Apton Biosystems

Aptose Biosciences

Aquinnah Pharmaceuticals

Arbor Biotechnologies

Arcadia Science

Arcellx

Arcturus Therapeutics

Arcutis Biotherapeutics

Arima Genomics

Ark Biotech

Arkuda Therapeutics

Armata Pharmaceuticals

Aro Biotherapeutics

Arpeggio Biosciences

Arrakis Therapeutics

Arranta Bio

ArsenalBio

Artisan Bio

Artiva Biotherapeutics

Ascidian Therapeutics

Ascribe Bioscience

Asher Biotherapeutics

Asimov

Pardes Biosciences is solving pandemic-sized problems. The outbreak of COVID-19 caused a significant global health crisis that demanded the fast development of antiviral treatments. Pardes is working to develop and commercialize antivirals for the treatment of coronavirus - as well as potential future pandemics and human diseases - using a combination of medicinal chemistry, structure-based drug design and virology. Drugs are identified using their chemistry platform that consists of “warheads” that enable the discovery of reversible covalent chemical bonding activity that enhances the activity and selectivity of drug candidates and reduces likely “off-target” reactions. Focusing on orally deployable drugs also helps to address disparities in care that exists in the treatment of many prevalent diseases.

<p>Pardes Biosciences is solving pandemic-sized problems. The outbreak of COVID-19 caused a significant global health crisis that demanded the fast development of antiviral treatments. Pardes is working to develop and commercialize antivirals for the treatment of coronavirus - as well as potential future pandemics and human diseases - using a combination of medicinal chemistry, structure-based drug design and virology. Drugs are identified using their chemistry platform that consists of “warheads” that enable the discovery of reversible covalent chemical bonding activity that enhances the activity and selectivity of drug candidates and reduces likely “off-target” reactions. Focusing on orally deployable drugs also helps to address disparities in care that exists in the treatment of many prevalent diseases.</p>


Pardes Biosciences

Find a biotech startup job.